Prelude Capital Management, LLC Burning Rock Biotech LTD Transaction History

Prelude Capital Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$2.15 - $3.16 $112,012 - $164,632	-52,099 Reduced 79.33%	13,577 $29,000
Q1 2023 May 15, 2023	BUY	$2.16 - $3.47 $71,038 - $114,121	32,888 Added 100.3%	65,676 $184,000
Q4 2022 Feb 14, 2023	SELL	$1.73 - $2.95 $153,333 - $261,464	-88,632 Reduced 73.0%	32,788 $73,000
Q3 2022 Nov 14, 2022	BUY	$2.39 - $3.96 $153,963 - $255,103	64,420 Added 113.02%	121,420 $290,000
Q2 2022 Aug 15, 2022	BUY	$1.75 - $10.44 $99,750 - $595,080	57,000 New	57,000 $166,000
Q1 2022 May 16, 2022	SELL	$6.7 - $10.23 $83,750 - $127,875	-12,500 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$17.37 - $27.92 $11,412 - $18,343	-657 Reduced 4.99%	12,500 $224,000
Q2 2021 Aug 16, 2021	BUY	$26.14 - $37.45 $17,173 - $24,604	657 Added 5.26%	13,157 $388,000
Q1 2021 May 17, 2021	BUY	$23.5 - $39.58 $44,720 - $75,320	1,903 Added 17.96%	12,500 $337,000
Q4 2020 Feb 16, 2021	SELL	$22.55 - $30.87 $39,688 - $54,331	-1,760 Reduced 14.24%	10,597 $245,000
Q3 2020 Nov 16, 2020	BUY	$19.07 - $29.61 $235,647 - $365,890	12,357 New	12,357 $310,000

21.2K

Ticker BNR
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 105,188,000
Market Cap $721M
Description
Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based cancer therapy selection and p...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.